Background and aims Probability discounting refers to the effect of outcome uncertainty on decision making. Using
INTRODUCTION
As major national and international health organizations have advocated for the availability of opioid medications for the treatment of chronic pain, the use of these medications has risen-especially in the United States [1] [2] [3] . Unfortunately, this increased use has been associated with the growing prevalence of opioid use disorder (OUD) and a steep rise in the incidence of opioid-related overdose deaths, with the number of annual overdose deaths overtaking motor vehicle accidents as the leading cause of accidental death in the United States [4] . The coverage of these statistics in the popular press and on-line media has been dramatic, most probably reaching the majority of chronic pain patients and opioid prescribers [5, 6] .
Given the aforementioned risks, regulatory bodies have advocated requiring informed consent conversations prior to initiating opioid medications for the treatment of chronic pain in an attempt to reduce overall opioid prescriptions and prevent harm [7] . Part of this process involves an appraisal of the potential development of OUD [8] , but the exact content of the conversation is left to the provider. However, communication between patients and providers about treatment is often equivocal [9] . For example, a preliminary risk assessment of opioid misuse may vary greatly between providers, if it is even addressed.
Little controlled research has examined how chronic pain patients (CPP) interpret conversations about addiction risk in determining when and if to initiate opioid therapy. The research surrounding CPP/provider interactions has focused primarily on other opioid side effects and satisfaction [10] , discontinuation of opioids once started [11] and reasons why prescribers choose or do not choose to prescribe opioids [12, 13] . Interestingly, chronic neuropathic pain patients identify the most important features of an analgesic medication to be pain relief, lack of nausea and lack of character change (or unusual behaviors) [14] , suggesting that chronic pain patients have preferences that include a consideration of medication risks and benefits. However, these preferences are often lost during standard brief patient/provider interactions, especially in emergency rooms [15, 16] .
There is a pressing need to quantify patient treatment preference, especially in a way that is generalizable to the chronic pain population and takes into consideration the benefits versus risks of a pharmacotherapy [15] . Therefore, this manuscript presents results from an on-line survey of self-identified CPP who completed a novel probability discounting task wherein they were asked to weigh the benefits of various durations of pain relief against the risk of addiction resulting from once-daily administration of a novel (and hypothetical) analgesic medication. Probability discounting is a behavioral process in which the uncertainty of an outcome affects decision-making, and is studied most often in the context of monetary choices in humans [16] , e.g. choice between certainty in receiving a small reward versus varying probability in receiving a large reward [17] . In the current study, the uncertainty of a negative outcome (developing addiction) was manipulated systematically and weighed against an increasing reward (duration of complete pain relief). The aims of this study were to: (1) compare the likelihood of trying a novel analgesic between self-identified CPP with either high or low risk of opioid misuse, (2) determine the association between state/trait measurements (e.g. chronic pain, impulsivity) and probability discounting of addiction risk and (3) determine whether previous opioid side effects are associated with willingness to try a novel analgesic.
METHODS

Design
In order to address the aims of this study, we designed a survey that could be distributed on-line to reach a diverse sample of self-identified CPP. The survey included a probability-discounting task that was specific to the relationship between duration of pain relief versus the risk of addiction. In addition, CPP were asked to describe their pain and answer several standardized questionnaires assessing their risk for opioid misuse, state/trait measurements of mental health and previous experience with prescription opioids (if any). The following sections characterize the patient population and describe the specific instruments utilized in the survey.
Participants
The study sample was composed of adults reporting chronic pain that resided in the United States, and registered as 'workers' on the Amazon Mechanical Turk (AMT) platform. AMT has been used in numerous biomedical research studies and produces a nationally representative, unbiased sample with valid results [18] [19] [20] [21] . It is quicker and less expensive to recruit participants; e.g. this study sample was recruited in 2 days and each participant was paid between $1.50 and $3.00 for survey completion. Within the AMT platform, 'human intelligence tasks' (HITs) are made available to 'workers' by 'requestors', who rate whether the worker has completed the task to satisfaction. For the present survey, at least a 95% past approval rating for previous work on AMT was required to accept the HIT. Participation was voluntary and anonymous, and consent was indicated via completion of the main on-line survey. The Johns Hopkins University Institutional Review Board approved this study.
Our prespecified desired number of completed surveys was 300, and 647 participants filled out a brief screening survey to achieve this number of completed surveys. The screening survey assessed basic entry criteria for the study, including accurate answers on two distractor questions. Eligibility criteria were: (1) age ≥ 18; (2) resident of the United States; and (3) presence of chronic pain. Pain was measured using a five-point scale consisting of 'none', 'mild', 'moderate', 'severe' and 'very severe'. Chronic pain was considered present if all the following criteria were met: (a) having pain present for at least 3 months, (b) reporting past-week pain intensity of at least moderate at its worst, (c) reporting at least mild pain on average and (d) reporting that the intensity of the last pain experienced was ≥ 2 (using an 11-point visual analog scale). All surveys were hosted on Qualtrics (Provo, UT, USA) and completed from 12 to 13 December 2014. A previously published paper from this sample reported on results from novel discounting tasks that assessed hypothetical pain-related rewards and punishments [22] .
Measures
Benefit versus Addiction Risk Questionnaire (BARQ)
The BARQ is a novel probability discounting task assessing one's likelihood of taking a hypothetical analgesic medication, given a duration of complete pain relief versus risk of developing addiction (please see Supporting information, Appendix S1 for exact instructions and instrument). Instructions prior to each set of questions asked the participant to imagine that a new analgesic medication has been approved for their pain condition, and that the medication is to be taken once daily by mouth. Instructions asked the participant to take questions seriously, to assume their current (personal) pain levels and to weigh benefits (duration of complete pain relief in days) with risks (developing addiction). Addiction was not defined for participants. For the 3-day pain relief condition, participants were asked a series of nine questions regarding risk of addiction; addiction risks included the following (in order of presentation): 0%; 1/10 000 (0.01%); 1/2000 (0.05%); 1/700 (0.14%); 1/400 (0.25%); 1/100 (1%); 1/13 (8%); 1/3 (33%); and 1/2 (50%). After each proposition, participants were asked to gauge whether or not they would take the analgesic using a 0-100 visual analog scale (VAS) that had the following anchors: 'Definitely not take' at 0 and 'Definitely take' at 100. This sequence of questions was repeated for conditions proposing 30 and 365 days of pain relief. The percentages of addiction risk corresponded largely to prior probability discounting research in our unit that produced orderly results on a sexual probability discounting task [22] . In addition, the BARQ probabilities encompass the range of addiction rates that have been reported for existing opioid analgesics [23, 24] .
SOAPP-R
Participants completed the validated Screener and Opioid Assessment for Patients in Pain-Revised (SOAPP-R) [25] . This 24-item scale assesses the frequency of risk factors that are predictive of misuse during an episode of opioid pain medication treatment. Although the SOAPP-R contains items that are face-valid for opioid misuse ('How often have you run out of pain medication early?'), it was designed intentionally to limit deception by patients [26] . For example, the SOAPP-R also contains questions on the frequency of 'tension in the home', arguments resulting in physical violence and impatience with doctors. For each risk factor, participants can answer 'never', 'seldom', 'sometimes', 'often' or 'very often'. The items are summed for a total score (range 0-96). Patients with a total score of ≥ 18 have been shown prospectively to be at greater risk for opioid misuse during treatment [27] . In the present study, total scores were calculated for the SOAPP-R, and a dichotomous variable for opioid misuse risk was created using established SOAPP-R cut-offs (≥ 18 or < 18). Table 1 shows differences in participant characteristics broken down by SOAPP-R category; individuals scoring ≥ 18 are considered to be at heightened risk for opioid misuse [27] .
Pain
Pain was measured comprehensively using several selfreport measures. First, the participants were asked questions about the frequency (how often and last time) as well as duration of chronic pain. Secondly, participants were given a list of body parts and asked to select all parts that were painful. Thirdly, participants were asked to choose from a list of conditions that caused their pain. Composite scores were created for total number of body parts experiencing pain as well as number of painful conditions. Fourthly, the participants filled out a modified version of the Brief Pain Inventory-Short Form (BPI) [28] . Primary pain syndrome was derived from the initial BPI; if necessary, participants filled out a second BPI if they reported a secondary pain syndrome. Pain interference and pain relief questions from the BPI were answered with the participant taking all their pain syndromes into consideration. Fifthly, participants completed the Pain Catastrophizing Scale (PCS)-a 13-item scale that assesses important affective and cognitive aspects of pain [29] . PCS total scores range from 0 to 52, with higher scores indicating heightened distress responses when exposed to aversive stimuli.
Mental health
Participants completed brief validated screening questionnaires for depression [(Patient Health Questionnaire (PHQ-2)] [30] and anxiety [Generalized Anxiety Disorder 7-item scale (GAD-7)] [31] . PHQ-2 scores range from 0 to 6, with higher scores indicating a higher likelihood of having a depressive disorder. GAD-7 scores range from 0 to 21, with higher scores indicating a higher likelihood of having GAD. In addition, participants completed a validated measure of trait impulsivity [Barratt Impulsiveness Scale (BIS-11)] [32] . The BIS-11 contains 30 brief behavioral descriptions, and results are characterized in three subscales-attentional, motor and non-planning. Lastly, participants completed the five-item Insomnia Severity Index (ISI) [33] [34] [35] , a validated measure of sleep problems. ISI total scores range from 0 to 28, with higher scores indicating a higher likelihood of clinical insomnia. Opioid use and side effects
Addiction risk and novel pain relievers
Participants were asked two questions about past experience (yes/no) and duration of experience with opioid medications. In addition, participants reporting experience with opioids (n = 174; 66% of sample) were also asked about frequency, level of distress and medication discontinuation as a result of common opioid side effects [36] .
Statistical analyses
Descriptive statistics were obtained by SOAPP-R category (< 18 or ≥ 18) for each of the demographic, pain, mental health, insomnia and opioid use variables. Where appropriate, Student's t-tests were performed for continuous variables and χ 2 or Fisher's exact tests for categorical variables to examine differences by SOAPP-R category. In addition, χ 2 or Fisher's exact tests were performed to examine opioid side effects by SOAPP-R category. Area under the curve (AUC) values were calculated for the three series of BARQ questions to compare the overall likelihood of taking an analgesic medication given the expected duration of complete pain relief (3, 30 or 365 days) using methods described previously for probability discounting, with possible values ranging from 0 to 1 [37] . Associations between the three AUC values and risk for opioid misuse were examined using the two-factor repeated-measures analysis of variance (ANOVA) with SOAPP-R category, days of pain relief and a SOAPP-R × days of pain relief interaction term as factors. Tukey's honestly significant difference (HSD) tests were used for planned post-hoc analyses.
As there were significant differences in AUC between respondents with high versus low SOAPP-R scores, regression analyses were performed to determine the independent effect of opioid misuse risk on the likelihood to try novel analgesics. Generalized linear model (GLM) analyses were used with an identity link, Gaussian distribution and robust standard error estimation to correct for non-normally distributed residuals of the regression model (STATA version 11.2; StataCorp, LLP, College Station, TX, USA). Separate GLM analyses were performed for the three AUC values. Predictors included SOAPP-R category, age, gender, sexual orientation, ethnicity, race, education, annual household income, duration of chronic pain, number of chronic pain diagnoses, last pain VAS, usual pain VAS, BPI severity rating for the primary pain, BPI interference VAS, whether or not a respondent had ever used opioids, PHQ-2 total score, GAD-7 total score, PCS total score and ISI total score. A preliminary investigation into the association between predictors and each AUC value was conducted using univariate GLM analyses with the same link and distribution as the subsequent multivariate analyses. The univariate analyses were not used in deciding which predictors to include in multivariate models. To build the three final multivariate models, stepwise backward selection was used, where predictors were removed from the model if P > 0.2. Each of the predictors used in the univariate analyses was placed in the multivariate model. The three final multivariate models were re-analyzed with all the included variables standardized in order to compare the relative effect of each variable on the outcome. 
RESULTS
Of the 300 completed surveys, 263 of them were retained for these analyses (Table 1) . Those surveys dropped included five in which the respondent did not report pain lasting > 3 months, eight people who filled out the survey twice and 24 people who failed prespecified quality control distractor questions. The following sections review the overall results and then separately by duration of pain relief specified for each series of questions (3, 30 or 365 days).
Overall likelihood of taking novel analgesic medication Figure 1a shows mean overall likelihood of taking a novel analgesic medication (as represented by AUC) by SOAPP-R category and by duration of expected pain relief. In repeated-measures ANOVA of AUCs, SOAPP-R category 1 and days of pain relief 2 were statistically significant whereas the day × SOAPP-R category trended towards significance. 3 In post-hoc analyses, participants with elevated SOAPP-R scores (≥ 18) showed significantly higher mean AUC, indicating a greater willingness to try the novel medication no matter the duration of pain relief provided compared to participants with low SOAPP-R scores. 4 In participants with elevated SOAPP-R scores, AUC in the 365-day condition (0.39) was significantly greater than the 3-day condition (0.33) but not the 30-day condition (0.36), whereas there were no significant differences between AUC values in participants with SOAPP-R scores < 18. These data suggest that CPP with a greater risk for opioid misuse increased willingness to try a novel medication as the magnitude of expected pain relief increased. However, the effect size of the SOAPP-R score by days of pain relief interaction was small. Figure 1b shows the effect of increasing addiction risk on the mean likelihood of taking a novel analgesic medication with 3 days of pain relief. Even with a 0% chance of addiction risk, not all respondents were willing to try this novel analgesic. The steepest decline in likelihood occurred as the stated risk for addiction grew from 1 to 33% for both groups of respondents. In addition, there was an almost threefold difference in likelihood of taking a novel medication between SOAPP-R groups if 3 days of pain relief was associated with a 50 : 50 likelihood of developing addiction (21.9 versus 7.6%). In univariate GLM analysis of AUC values, several factors were associated with propensity to try a novel analgesic (Table 2) ; however, participants with higher levels of education were significantly less likely to try novel medication. In multivariate model building, gender, SOAPP-R scores, last pain VAS, ISI total score, number of pain diagnoses, BPI pain severity of primary pain condition and the attentional and non-planning subscales of the BIS-11 were retained in final model (see Table 3 for results). Thus, respondents with greater risk for opioid misuse were more willing to try a novel analgesic medication that had addiction risk compared to people with lower risk of opioid misuse, even after controlling for pain level and severity and personality measures of impulsivity. Figure 1c shows the effect of increasing addiction risk on the mean likelihood of taking a novel once-daily oral analgesic medication with 30 days of complete pain relief. These curves are similar to the 3-day pain relief curves, with high SOAPP-R respondents more likely to take the novel medication at each addiction risk > 0%.
Three-day pain relief
Thirty-day pain relief
In univariate GLM analysis of AUC values (Table 2) , the same variables that were significant for 3 days were significant for novel medication providing 30 days of complete pain relief. In multivariate model building, gender, SOAPP-R scores, last pain VAS, ISI total score and number of pain diagnoses were retained in the final model (see Table 3 for results).
Three hundred and sixty-five-day pain relief Figure 1d shows the effect of increasing addiction risk on the mean likelihood of taking a novel analgesic medication with 365 days (1 year) of complete pain relief. As in the 3-and 30-day conditions, respondents with high SOAPP-R scores were more likely to take the novel medication at each addiction risk > 0%.
In univariate GLM analysis of AUC values, most variables that were significant in 3-and 30-day analyses remained significant (Table 2 ). In multivariate model building, gender, SOAPP-R score, education, duration of chronic pain, PHQ-2 total score and BPI pain interference composite score were retained in the final model (see Table 3 for results).
Prior opioid side effects
Of the 174 respondents who had a past history using opioid medications, the most common side effects reported were drowsiness, lightheaded/dizzy and fatigued/weak (Table 4) . People with high SOAPP-R scores reported overall more total side effects [high versus low mean (95% CI) = 7.6 (7.0, 8.3) versus 6 (5.3, 6.6), P = 0.001], but they reported that they were less likely to stop the opioids due to side effects compared to people with low scores. There were statistically significant differences between groups in levels of distress from side effects (Table 4) . Only nausea was associated with a significantly lower percentage of high versus low SOAPP-R respondents in stopping opioid use (Table 4 ). In exploratory GLM regression analysis of AUC values, final models were re-run only on participants with past opioid exposure with the addition of number of opioid side effects. The number of past opioid side effects was associated with significantly reduced willingness to try novel pain medication with 30 and 365 days of complete pain relief, but not 3 days e .
DISCUSSION
The central finding of these analyses is that self-identified CPP who are at high risk for opioid misuse (SOAPP-R score ≥ 18) are more likely to try novel analgesic medications at a range of addiction risk probabilities when compared to individuals at low risk for opioid misuse. In multivariate analysis, the association between probability discounting AUC and SOAPP-R scores remained significant even when accounting for respondents' pain severity, pain interference and pain catastrophizing (Tables 3-5) . High scores on the non-planning BIS-11 subscale were also associated with propensity to try novel analgesics ( Table 1 ), suggesting that patients with higher trait impulsivity are more likely to discount the probability of becoming addicted as a potential medication side effect. In addition, self-identified CPP who had experienced other opioid side effects previously were less likely to try a novel analgesic, even though the novel analgesic medications proposed in this study were not identified as opioids.
Individuals at high risk for opioid misuse might be more prone to risky decision-making in general [17, 23] , as a prior paper derived from these same survey respondents found greater discounting of delayed punishments (both pain-and money-related) when comparing CPP with high versus low risk for opioid misuse [21] . From a clinical standpoint, high-risk individuals might be more likely to ask about or try to influence physicians in seeking medications that have high abuse potential if they view these medications as a reward [38] . Indeed, high-risk individuals have more risk tolerance for every hypothetical proposition in the BARQ (Fig. 1) .
Trait factors of impulsivity, measured by the BIS-11, were elevated in CPP at high risk for opioid misuse (Table 1 ). In addition, scores on the BIS-11 were also associated with increased willingness to try a novel analgesic (Table 2) . Although a small effect, CPP at high risk for opioid misuse were more likely to try a novel analgesic with elevated addiction risk if the duration of pain relief was increased (thus, increased reward); this phenomenon was not found in low-risk CPP, suggesting that low-risk CPP may make decisions based mainly on risk of addiction (Fig. 1d) . It is well established that trait impulsivity is predictive of development of substance use disorders (SUDs) [39, 40] , a finding that has recently been extended to the development of opioid misuse in CPP [41] . Similarly, research on probability discounting has echoed the relationship between SUDs and risky decision-making [22, 42] . For example, a recent study by Johnson et al.
found that alcohol use increases the probability discounting of acquiring a sexually transmitted disease by forgoing condom-protected sex [42] . The probability discounting approach used in our study is the first, to our knowledge, to examine choice of medication in selfidentified CPP, and might be comparable to discrete choice experiments in so far as the goal is to establish trade-offs that the participant is willing to make, i.e. weighing risk against reward [43] . The current study paradigm weighs the probability of risk of addiction in a way that is not time-dependent and appears to have more influence over the decision-making process than the reward of protracted pain relief (see Fig. 1d ). In addition to state/trait measurements, previous experience with opioid side effects was associated with willingness to try a novel analgesic that provided 30 or 365 days of complete pain relief. More specifically, CPP at low risk for opioid misuse reported fewer side effects during prior opioid use; however, these same individuals were more likely to have stopped taking opioids in the past due to a side effect (e.g. nausea; Table 4 ). These results point to the importance that prior experience has on trying a new analgesic medication.
Previous clinical research has shown that CPP have a high desire for information regarding their care, particularly in premedication visits [44] . However, physicians often fail to collect and relay critical information regarding patient needs and experiences. Many physicians may be unsure how to address risk factors when interacting with Not all participants had previously used prescription opioids to manage pain (n = 174 of the total sample n = 263). Participants are split into low risk for opioid misuse (low SOAPP-R) and high risk for opioid misuse (high SOAPP-R). *P < 0.05; **P < 0.10 comparing low versus high SOAPP-R (Screener and Opioid Assessment for Patients with Pain-Revised).
CPP. For instance, primary-care physicians often feel ill-prepared to prescribe opioids and may avoid the topic altogether during patient visits [45] . Similarly, physicians in community clinical settings frequently cite issues such as lack of self-management and abuse potential as reasons why they are wary of prescribing opioids long-term to CPP [46] . While physicians should seek to inform patients about all risks, it is likely that increased emphasis of the abuse potential in the informed consent process may actually decrease the number of low-risk CPP willing to utilize opioids to manage chronic pain, even though they would be at lower risk for abusing opioids. Engaging in open dialogue during consent could be used as a way to guide low-risk individuals into effective treatments, while high-risk individuals can be flagged for monitoring from the beginning of treatment or offered alternative treatments than opioids. Individuals who are eager to try a medication despite elevated addiction risk might be another indication that they are at high risk for medication misuse.
This study has some limitations. The use of AMT workers may or may not be representative of the chronic pain population as a whole, although the participant demographics and variety of chronic pain syndromes are similar to other large samples [47, 48] . In addition, surveys were conducted anonymously, without verification from a clinician or treatment center of a chronic pain diagnosis; conversely, this procedure allowed sampling several types of self-identified CPP who might not be treated in specialty clinics, and anonymity is likely to facilitate truthful responding. It is also possible that the results from this study are influenced at least partially by common-method variance, in that both the outcome variable and predictor of interest (SOAPP-R) were self-reported during an anonymous survey. Also, our survey did not define addiction, although most primary-care physicians also do not define addiction in their practice, which suggests that leaving the definition of addiction to the participant replicates real-world decision-making. Lastly, we did not define the novel medication as an opioid; therefore, differing results may have occurred if the class of novel medication had been defined.
This study is a promising step towards understanding the decision-making process that underlies medication choice in a chronic pain population. Individuals at the highest risk for opioid misuse are also the most likely to discount addiction risk when choosing a pharmacotherapy. Other factors, such as trait impulsivity, pain interference and previous experience with opioid medications, also shape this decision-making process. Physicians should seek to tailor informed consent discussions in a way that cautions the use of medications with heightened abuse liability; our data show that individuals at high risk for opioid misuse might gravitate towards medications with high abuse potential, while relatively low-risk individuals will be less likely to utilize them. However, it is the low-risk individuals who could possibly benefit from these medications without misusing them. In addition, the study provides evidence that the FDA labeling process for immediate-release opioids [49] (which details both risks and benefits) may have unintended consequences, as the emphasis of addiction in the black box warning may increase the proportion of opioid patients at high risk for opioid misuse receiving prescriptions for these medications. Future controlled investigations on drug labeling are needed.
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